Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • Rights Issue 2022
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
      • Management stories
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Rights Issue 2022
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Press Releases
  • Regulatory Releases
  • All releases
2016
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
June 3, 2016

Oasmia Pharmaceutical announces early publication of Annual Report

Non Regulatory
April 29, 2016

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

Non Regulatory
April 15, 2016

Oasmia successfully completes private placements of new convertible instruments and new shares in the total amount of SEK 45,5 million

Non Regulatory
March 10, 2016

Clarification regarding Press Release about Ovarian Cancer Market

Non Regulatory
March 10, 2016

Oasmia Pharmaceutical Seeks to Fill Void in Ovarian Cancer Treatment Market Indicated in Recent National Academy of Medicine Report

Non Regulatory
February 29, 2016

Oasmia Pharmaceutical Reissues Executive Summary

Non Regulatory
February 8, 2016

Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

Non Regulatory
February 4, 2016

Oasmia Pharmaceutical to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference and BIO CEO & Investor Conference in New York

Non Regulatory
January 11, 2016

Oasmia Pharmaceutical AB (Nasdaq: OASM) to Ring the Nasdaq Stock Market Opening Bell on January 11

Non Regulatory
January 4, 2016

Oasmia Submits Application for Market Approval of its Next Generation Anti-Cancer Drug Doxophos® in Russia

Investor contact

Cord Communications
IR@vivesto.com
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com